Lupin announced the receipt of the Establishment
Inspection Report (EIR) from the USFDA for its Nagpur facility. The facility was inspected by the USFDA between
05 August 2019 and 08 August 2019.
The inspection for the oral solid facility at Nagpur closed without any Form 483 observation. The Nagpur facility is Lupin's largest and most advanced ora l solid dosage faci lity and has maintained a solid track record of compliance.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
